Vaxart, Inc. Proceeds from Common Stock Issued
Vaxart, Inc. (VXRT) reported Proceeds from Common Stock Issued of $1.43 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-04.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2023-05-04
- Vaxart, Inc. proceeds from issuance of common stock for the quarter ending 2023-03-31 was $1.43M, a 44.15% increase year-over-year.
- Vaxart, Inc. proceeds from issuance of common stock for the quarter ending 2022-12-31 was $8.59M.
- Vaxart, Inc. proceeds from issuance of common stock for the quarter ending 2022-09-30 was $4.85M, a 76.09% decline year-over-year.
- Vaxart, Inc. proceeds from issuance of common stock for the quarter ending 2022-06-30 was $2.81M, a 92.25% decline year-over-year.
- Vaxart, Inc. proceeds from issuance of common stock for fiscal 2022 was $17.24M, a 85.90% decline from fiscal 2021.
- Vaxart, Inc. proceeds from issuance of common stock for fiscal 2021 was $122.21M, a 1231.99% increase from fiscal 2020.
- Vaxart, Inc. proceeds from issuance of common stock for fiscal 2020 was $9.18M, a 261.22% increase from fiscal 2019.
- Vaxart, Inc. proceeds from issuance of common stock for fiscal 2019 was $2.54M.
| Period end | Proceeds from Issuance of Common Stock | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 12 month as first filed |
|---|---|---|---|---|---|---|
| 2023-03-31 | $1.43M 10-Q · filed 2023-05-04 | $10.02M derived: sum of 2 quarters · filed 2023-05-04 | $14.87M derived: sum of 3 quarters · filed 2023-05-04 | $17.68M derived: sum of 4 quarters · filed 2023-05-04 | ||
| 2022-12-31 | $8.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $13.44M derived: sum of 2 quarters · filed 2023-03-15 | $16.25M derived: sum of 3 quarters · filed 2023-03-15 | $17.24M 10-K · filed 2023-03-15 | ||
| 2022-09-30 | $4.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $7.66M derived: sum of 2 quarters · filed 2022-11-09 | $8.65M 10-Q · filed 2022-11-09 | $8.65M derived: sum of 4 quarters · filed 2023-05-04 | ||
| 2022-06-30 | $2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $3.80M 10-Q · filed 2022-08-08 | $3.80M derived: sum of 3 quarters · filed 2023-05-04 | $24.09M derived: sum of 4 quarters · filed 2023-05-04 | ||
| 2022-03-31 | $992.00K 10-Q · filed 2023-05-04 | $992.00K derived: sum of 2 quarters · filed 2023-05-04 | $21.29M derived: sum of 3 quarters · filed 2023-05-04 | $57.49M derived: sum of 4 quarters · filed 2023-05-04 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $20.30M derived: sum of 2 quarters · filed 2023-03-15 | $56.50M derived: sum of 3 quarters · filed 2023-03-15 | $122.21M 10-K · filed 2023-03-15 | $0.00 10-K · filed 2022-02-24 | |
| 2021-09-30 | $20.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $56.50M derived: sum of 2 quarters · filed 2022-11-09 | $122.21M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $36.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $101.91M 10-Q · filed 2022-08-08 | ||||
| 2021-03-31 | $65.71M 10-Q · filed 2022-05-09 | |||||
| 2020-12-31 | $9.18M 10-K · filed 2022-02-24 | |||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $9.18M 10-Q · filed 2020-08-06 | $9.18M derived: sum of 3 quarters · filed 2022-02-24 | $9.18M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2020-03-31 | $9.18M 10-Q · filed 2020-05-12 | $9.18M derived: sum of 2 quarters · filed 2022-02-24 | $9.18M derived: sum of 3 quarters · filed 2022-02-24 | $9.18M derived: sum of 4 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | $2.54M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2020-08-06 | $2.54M 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $2.54M 10-Q · filed 2020-08-06 | ||||
| 2019-04-11 | $9.30M 10-Q · filed 2019-08-08 | |||||
| 2019-03-31 | $2.54M 10-Q · filed 2020-05-12 | |||||
| 2019-03-20 | $2.50M 10-K · filed 2022-02-24 | |||||
| 2014-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-13 | $26.80M 10-K · filed 2016-09-13 | ||||
| 2014-03-31 | $26.80M 10-Q · filed 2015-05-08 | |||||
| 2013-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-27 | $0.00 derived: sum of 2 quarters · filed 2013-09-27 | $27.00M 10-K · filed 2013-09-27 | |||
| 2013-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-05-10 | $27.00M 10-Q · filed 2013-05-10 | ||||
| 2012-12-31 | $27.00M 10-Q · filed 2013-02-11 | |||||
| 2011-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-14 | $138.00K derived: sum of 2 quarters · filed 2012-03-14 | $368.00K derived: sum of 3 quarters · filed 2012-08-09 | $663.00K 10-K · filed 2012-03-14 | ||
| 2011-09-24 | $121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-02 | $351.00K derived: sum of 2 quarters · filed 2012-08-09 | $646.00K 10-Q · filed 2012-11-08 | $878.00K derived: sum of 4 quarters · filed 2012-08-09 | ||
| 2011-06-30 | $700.00K 10-K · filed 2013-09-27 | |||||
| 2011-06-25 | $230.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $525.00K 10-Q · filed 2012-08-09 | $757.00K derived: sum of 3 quarters · filed 2012-08-09 | $758.00K derived: sum of 4 quarters · filed 2012-08-09 | ||
| 2011-03-26 | $295.00K 10-Q · filed 2012-05-10 | $527.00K derived: sum of 2 quarters · filed 2012-05-10 | $528.00K derived: sum of 3 quarters · filed 2012-05-10 | |||
| 2010-12-25 | $232.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-14 | $233.00K derived: sum of 2 quarters · filed 2012-03-14 | $645.00K 10-K · filed 2012-03-14 | |||
| 2010-09-25 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-02 | $413.00K 10-Q · filed 2011-11-02 | ||||
| 2010-06-26 | $412.00K 10-Q · filed 2011-08-03 | |||||
| 2009-12-26 | $528.00K 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |